Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study.

Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, Baggs J, Weinmann S, Baxter R, Nordin J, Daley MF, Jackson L, Jacobsen SJ; Vaccine Safety Datalink (VSD) Team.

J Intern Med. 2012 May;271(5):510-20. doi: 10.1111/j.1365-2796.2011.02474.x. Epub 2011 Nov 22.

2.

Allergic reactions to Japanese encephalitis vaccine.

Plesner AM.

Immunol Allergy Clin North Am. 2003 Nov;23(4):665-97. Review. Erratum in: Immunol Allergy Clin North Am. 2004 May;24(2):335.

PMID:
14753386
3.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.

MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.

4.

Safety of Zostavax™--a cohort study in a managed care organization.

Baxter R, Tran TN, Hansen J, Emery M, Fireman B, Bartlett J, Lewis N, Saddier P.

Vaccine. 2012 Oct 19;30(47):6636-41. doi: 10.1016/j.vaccine.2012.08.070. Epub 2012 Sep 8.

PMID:
22963800
5.

Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.

Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, Stek JE, Schlienger K, Chan IS, Silber JL.

Vaccine. 2010 Jun 7;28(25):4204-9. doi: 10.1016/j.vaccine.2010.04.003. Epub 2010 Apr 21.

PMID:
20416263
6.

Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease.

Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ.

JAMA. 2011 Jan 12;305(2):160-6. doi: 10.1001/jama.2010.1983.

PMID:
21224457
7.

Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.

Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR.

JAMA. 2012 Jul 4;308(1):43-9. doi: 10.1001/jama.2012.7304.

8.

Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine.

Tseng HF, Smith N, Sy LS, Jacobsen SJ.

Vaccine. 2011 May 9;29(20):3628-32. doi: 10.1016/j.vaccine.2011.03.018. Epub 2011 Mar 22.

PMID:
21435407
9.

Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.

Tyring SK, Diaz-Mitoma F, Padget LG, Nunez M, Poland G, Cassidy WM, Bundick ND, Li J, Chan IS, Stek JE, Annunziato PW; Protocol 009 Study Group.

Vaccine. 2007 Feb 26;25(10):1877-83. Epub 2006 Oct 30.

PMID:
17227688
10.

H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project.

Lee GM, Greene SK, Weintraub ES, Baggs J, Kulldorff M, Fireman BH, Baxter R, Jacobsen SJ, Irving S, Daley MF, Yin R, Naleway A, Nordin JD, Li L, McCarthy N, Vellozzi C, Destefano F, Lieu TA; Vaccine Safety Datalink Project.

Am J Prev Med. 2011 Aug;41(2):121-8. doi: 10.1016/j.amepre.2011.04.004.

PMID:
21767718
11.

Herpes zoster vaccine: clinical trial evidence and implications for medical practice.

Burke MS.

J Am Osteopath Assoc. 2007 Mar;107(3 Suppl 1):S14-8. Review.

PMID:
17488883
12.

Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-BarberĂ  J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC; ZOE-50 Study Group.

N Engl J Med. 2015 May 28;372(22):2087-96. doi: 10.1056/NEJMoa1501184. Epub 2015 Apr 28.

13.

Community and patient values for preventing herpes zoster.

Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, Prosser LA.

Pharmacoeconomics. 2008;26(3):235-49.

PMID:
18282017
14.

Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.

Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley MF, Klein NP, Weintraub ES.

Vaccine. 2011 Oct 26;29(46):8279-84. doi: 10.1016/j.vaccine.2011.08.106. Epub 2011 Sep 9.

PMID:
21907257
15.

Vaccination: a new option to reduce the burden of herpes zoster.

Mick G.

Expert Rev Vaccines. 2010 Mar;9(3 Suppl):31-5. doi: 10.1586/erv.10.32. Review.

PMID:
20192716
16.

Risk of anaphylaxis after vaccination of children and adolescents.

Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, Mullooly JP, Thompson RS; Vaccine Safety Datalink Team.

Pediatrics. 2003 Oct;112(4):815-20.

PMID:
14523172
17.

Zoster vaccine in older adults.

Fried R.

J Am Geriatr Soc. 2010 Sep;58(9):1799-800. doi: 10.1111/j.1532-5415.2010.03023.x. No abstract available.

PMID:
20863342
18.

Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team.

Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM, Marcy SM, Ward JI, Wise RP, Wassilak SG, Hadler SC.

Pediatrics. 1997 Jun;99(6):765-73.

PMID:
9164767
19.

Vaccination against zoster remains effective in older adults who later undergo chemotherapy.

Tseng HF, Tartof S, Harpaz R, Luo Y, Sy LS, Hetcher RC, Jacobsen SJ.

Clin Infect Dis. 2014 Oct;59(7):913-9. doi: 10.1093/cid/ciu498. Epub 2014 Aug 4.

20.

The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study.

Zhang J, Delzell E, Xie F, Baddley JW, Spettell C, McMahan RM, Fernandes J, Chen L, Winthrop K, Curtis JR.

Arthritis Res Ther. 2011;13(5):R174. doi: 10.1186/ar3497. Epub 2011 Oct 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk